OncoMatch/Clinical Trials/NCT06475300
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
Is NCT06475300 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including BL-B01D1 and PD-1 Monoclonal Antibody for non-small cell lung cancer.
Treatment: BL-B01D1 · PD-1 Monoclonal Antibody — This phase II study is a clinical study to explore the efficacy and safety of BL-B01D1 combined with PD-1 Monoclonal Antibody in patients with locally advanced or metastatic non-small cell lung cancer, nasopharyngeal carcinoma and other solid tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Head and Neck Squamous Cell Carcinoma
Tumor Agnostic
Biomarker criteria
Excluded: ALK fusion
Excluded: EGFR sensitizing mutation
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic chemotherapy
Stage 1 EGFR-sensitive mutant non-small cell lung cancer patients with systemic chemotherapy
Cannot have received: systemic therapy
Stage 2 patients who had received previous systemic therapy
Cannot have received: anti-tumor therapy (chemotherapy, biological therapy, mitomycin, nitrosoureas, fluorouracil class oral drugs)
Anti-tumor therapy such as chemotherapy or biological therapy has been used within 4 weeks or 5 half-lives before the first dose; Mitomycin and nitrosoureas were administered within 6 weeks before the first dose; Fluorouracil class oral drugs, etc.
Lab requirements
Cardiac function
no serious cardiac dysfunction, left ventricular ejection fraction 50% or higher
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify